ReviewFrontiers in immunology2026
Regulatory T cells in vitiligo: a review of functional disequilibrium between peripheral blood and lesional tissue.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Vitiligo is an autoimmune skin disorder driven by CD8 Methods: This review synthesizes published evidence on Treg biology and immunoregulatory functions, focusing on comparative analyses between peripheral blood and lesional skin of vitiligo patients. We also examine Treg-melanocyte interaction networks, Treg-targeted therapies, and the potential of Treg-related biomarkers. Results: In peripheral blood, vitiligo patients exhibit reduced Treg frequency, impaired suppressive capacity, and Th1-like polarization, alongside dysfunctional subsets such as STAM (signal-transducing adaptor molecule) Discussion: The anatomical hierarchy of Treg dysregulation-from blood to skin-underscores that effective immunosuppression requires not only sufficient Treg numbers but also precise tissue localization and functional adaptation. Future single-cell transcriptomics and functionally defined Treg subsets may facilitate translation of Treg-based biomarkers and therapies into practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.